Genomma Lab InternacionalB de CVMEX:LABB -0.47%66 5-Year Yield-on-Cost % is 5.34 as of Jun. 28, 2026, which is 19% above its 10-year median of 4.47. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.64 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 517 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks better than 73.31% on this metric.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's 5-Year Yield-on-Cost % or its related term are showing as below:
MEX:LABB'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.8 Med: 4.47 Max: 11.6
Current: 5.34
During the past 13 years, Genomma Lab InternacionalB de CV's highest Yield on Cost was 11.60. The lowest was 2.80. And the median was 4.47.
MEX:LABB's 5-Year Yield-on-Cost % is ranked better than 73.31% of 517
companies
in the Drug Manufacturers industry
Industry Median: 2.43
vs MEX:LABB: 5.34
Genomma Lab InternacionalB de CV (MEX:LABB) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Genomma Lab InternacionalB de CV 5-Year Yield-on-Cost % Related Terms
MEX:LABB vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's 5-Year Yield-on-Cost % falls into.
Genomma Lab InternacionalB de CV 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Genomma Lab InternacionalB de CV (MEX:LABB) has a 5-Year Yield-on-Cost % of 5.34 as of Jun. 28, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 19% above median its historical median of 4.47. Over the past decade, Genomma Lab InternacionalB de CV's 5-Year Yield-on-Cost % has ranged from 2.80 to 11.60. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #138 out of 517 companies in the Drug Manufacturers industry, placing it in the top 26.7%.
Is Genomma Lab InternacionalB de CV's 5-Year Yield-on-Cost % too high?
Genomma Lab InternacionalB de CV's current 5-Year Yield-on-Cost % of 5.34 is 19% above median its 10-year median of 4.47. Over the past 10 years, this metric has ranged from a low of 2.80 to a high of 11.60. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.43. Genomma Lab InternacionalB de CV's value of 5.34 is 119.8% above this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #138 out of 517 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #138 out of 517 companies for 5-Year Yield-on-Cost %. This puts Genomma Lab InternacionalB de CV in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.43. Genomma Lab InternacionalB de CV's value of 5.34 is 119.8% above this benchmark. Historically, Genomma Lab InternacionalB de CV's own 5-Year Yield-on-Cost % has ranged from 2.80 to 11.60 over the past decade. While the company's 10-year median is 4.47 vs. the industry median of 2.43, Genomma Lab InternacionalB de CV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.43, based on 517 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current 5-Year Yield-on-Cost % of 5.34 is 119.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current 5-Year Yield-on-Cost % is 5.34, which is 19% above median its own 10-year median of 4.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN14.97 — trading 15.1% below its estimated fair value. The current 5-Year Yield-on-Cost % is 5.34, which is 19% above median its 10-year median of 4.47 and 119.8% above the Drug Manufacturers industry median of 2.43. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current 5-Year Yield-on-Cost % is 5.34 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN14.97 is trading 15.1% below its estimated GF Value™ of MXN17.64.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
5-Year Yield-on-Cost %: 5.34 (19% above median its 10-year median of 4.47)
GF Value™: MXN17.64 vs. price of MXN14.97 (15.1% below fair value)
Industry Position: 119.8% above the Drug Manufacturers median (#138 of 517)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 